Boston Scientific stock price slides again as $14.5B Penumbra deal puts debt, dilution in focus
Boston Scientific shares fell 2.18% to $88.07, their seventh straight decline, after announcing a $14.5 billion deal to acquire Penumbra. The company expects the acquisition to reduce adjusted earnings per share by $0.06–$0.08 in the first year. U.S. markets will close Monday for Martin Luther King Jr. Day.